Unum Therapeutics Inc. (UMRX) Reports Q3 Loss of $0.34, Revenues Miss

Unum Therapeutics Inc. (NASDAQ: UMRX) reported Q3 EPS of ($0.34), versus $0.00 reported last year. Revenue for the quarter came in at $2.04 million versus the consensus estimate of $2.33 million.

“In the third quarter of 2018, we continued to make significant progress advancing our clinical pipeline,” said Chuck Wilson, CEO of Unum. “We are excited to announce today that we have selected ACTR707 in combination with rituximab for further development in patients with relapsed or refractory non-Hodgkin lymphoma. Early data from the ATTCK-20-03 trial continue to support our novel ACTR platform and potential best-in-class product profile. In addition, we remain on track with our two additional clinical studies, ATTCK-17-01 in multiple myeloma and ATTCK-34-01 in HER2+ solid tumors, and are looking forward to presenting further updates on all trials at upcoming scientific conferences in December. Finally, we are pleased with our significant progress in developing a second novel technology platform, BOXR, which is designed to improve T cell functionality in solid tumors, and we look forward to developing future products based on this platform.”

For earnings history and earnings-related data on Unum Therapeutics Inc. (UMRX) click here.

You May Also Be Interested In

• Netflix climbs following Ackman stake, up 1.8%
• Pyxis Oncology, Inc. (PYXS) Misses Q2 EPS by 4c
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance